Molecular classification of hepatocellular carcinoma

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages 234-241

  Zucman Rossi, Jessica ^a,b  

^a Labex Immuno Oncology   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Hepatocellular carcinoma; MiRNA; Molecular classification; Oncogene; Transcriptome; Tumour suppressor gene

Indexed keywords

MESSENGER RNA; MICRORNA; PROTEIN P53;

ARTICLE; CANCER CLASSIFICATION; DNA METHYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; ONCOGENE; PRIORITY JOURNAL; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE; CLASSIFICATION; GENETICS; LIVER TUMOR; MUTATION; PHYSIOLOGY;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; MICRORNAS; MUTATION; ONCOGENES;

EID: 77953693531     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.05.020     Document Type: Letter

References (104)

1. Vogelstein B, Kinzler KW Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
2. Laurent-Puig P, Zucman-Rossi J Genetics of hepatocellular tumors. Oncogene 2006, 25:3778-3786.
3. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008, Chapter 10: Unit 10 1.
4. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002, 32:312-315.
5. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gpl30 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
6. Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor lalpha inactivation. Gas-troenterology 2003, 125:1470-1475.
7. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
8. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416.
9. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
10. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Nati Acad Sei U S A 1998, 95:8847-8851.
11. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998, 58:2524-2527.
12. Nagafuchi A, Takeichi M Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1989, 1:37-44.
13. Micsenyi A, Tan X, Sneddon T, et al. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 2004, 126:1134-1146.
14. Suksaweang S, Lin CM, Jiang TX, et al. Morphogenesis of chicken liver: identification of localized growth zones and the role of beta-catenin/Wnt in size regulation. Dev Biol 2004, 266:109-122.
15. Monga SP, Monga HK, Tan X, et al. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003, 124:202-216.
16. Benhamouche S, Decaens T, Godard C, et al. Ape tumor suppressor gene is the " zonation-keeper" of mouse liver. Dev Cell 2006, 10:759-770.
17. Cadoret A, Ovejero C, Terris B, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002, 21:8293-8301.
18. Monga SP, Pediaditakis P, Mule K, et al. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001, 33:1098-1109.
19. Tan X, Behari J, Cieply B, et al. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006, 131:1561-1572.
20. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
21. Legoix P, Bluteau O, Bayer J, et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999, 18:4044-4046.
22. Audard V, Grimber G, Elie C, et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007, 212:345-352.
23. Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009, 49:821-831.
24. Fujito T, Sasaki Y, Iwao K, et al. Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma. Hepatogas-troenterology 2004, 51:921-924.
25. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000, 157:763-770.
26. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa [see comments]. Nature 1991, 350:429-431.
27. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991, 350:427-428.
28. Bluteau O, Beaudoin J-C, Pasturaud P, et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 2002, 21:1225-1232.
29. Chen YW, Jeng YM, Yeh SH, et al. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002, 36:927-935.
30. Laurent-Puig P, Plomteux O, Bluteau O, et al. Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. Gastroenterology 2003, 124:1311-1314.
31. Rebouissou S, Rosty C, Lecuru F, et al. Mutation of TCF1 encoding hepatocyte nuclear factor lalpha in gynecological cancer. Oncogene 2004, 23:7588-7592.
32. Rebouissou S, Vasiliu V, Thomas C, et al. Germline hepatocyte nuclear factor lalpha and lbeta mutations in renal cell carcinomas. Hum Mol Genet 2005, 14:603-614.
33. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. Hepatology 2009, 50(2):481-489.
34. Van der Borght S, Libbrecht L, Katoonizadeh A, et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007, 51:855-856.
35. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.
36. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
37. Yakicier Y, Legoix P, Vaury C, et al. Identification of homozygous deletions at chromosome 16q23 in Aflatoxin Bl exposed hepatocellular carcinoma. Oncogene 2001, 20:5232-5238.
38. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002, 13:1929-1939.
39. Breuhahn K, Vreden S, Haddad R, et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 2004, 64:6058-6064.
40. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. The Journal of clinical investigation 2006, 116:1582-1595.
41. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008, 68:6779-6788.
42. Coulouarn C, Factor VM, Thorgeirsson SS Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008, 47:2059-2067.
43. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008, 68:1451-1461.
44. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004.
45. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
46. Cullen BR Transcription and processing of human microRNA precursors. Mol Cell 2004, 16:861-865.
47. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and onco-gene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
48. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
49. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006, 99:671-678.
50. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
51. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin Gl is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007, 67:6092-6099.
52. Huang YS, Dai Y, Yu XF, et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol 2008, 23:87-94.
53. Wang Y, Lee AT, Ma JZ, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008, 283:13205-13215.
54. Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008, 14:419-427.
55. Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47:1223-1232.
56. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008, 173:856-864.
57. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
58. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
59. Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50:472-480.
60. Ura S, Honda M, Yamashita T, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
61. Huang XH, Wang Q, Chen JS, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009, 39:786-794.
62. Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumori-genicity. Cancer Res 2009, 69:1135-1142.
63. Coulouarn C, Factor VM, Andersen JB, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
64. Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999, 155:1795-1801.
65. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21:4863-4871.
66. Terris B, Pineau P, Bregeaud L, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999, 18:6583-6588.
67. Wong CM, Fan ST, Ng IO beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136-145.
68. Challen C, Guo K, Collier JD, et al. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992, 14:342-346.
69. Leon M, Kew MC Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res 1995, 15:859-861.
70. Takada S, Koike K Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. Oncogene 1989, 4:189-193.
71. Tsuda H, Hirohashi S, Shimosato Y, et al. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989, 80:196-199.
72. Weihrauch M, Benicke M, Lehnert G, et al. Frequent k-ras-2 mutations and pl6(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001, 84:982-989.
73. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
74. Tanaka Y, Kanai F, Tada M, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006, 25:2950-2952.
75. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999, 59:307-310.
76. Yang DH, Huang W, Cui J, et al. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004, 3:86-89.
77. Hayashi H, Sugio K, Matsumata T, et al. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatol-ogy 1995, 22:1702-1707.
78. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998, 77:776-782.
79. Hussain SP, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
80. Chen TC, Hsieh LL, Kuo TT, et al. pl6INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma. Anticancer Res 2000, 20:1621-1626.
81. Kita R, Nishida N, Fukuda Y, et al. Infrequent alterations of the pl6INK4A gene in liver cancer. Int J Cancer 1996, 67:176-180.
82. Liew CT, Li HM, Lo KW, et al. High frequency of pl6INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999, 18:789-795.
83. Ishizaki Y, Ikeda S, Fujimori M, et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol 2004, 24:1077-1083.
84. Kim YD, Park CH, Kim HS, et al. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23:110-118.
85. Park JY, Park WS, Nam SW, et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005, 25:70-76.
86. Satoh S, Daigo Y, Furukawa Y, et al. AXINl mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXINl. Nat Genet 2000, 24:245-250.
87. Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axinl and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007, 26:774-780.
88. Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994, 54:4177-4182.
89. Kawate S, Takenoshita S, Ohwada S, et al. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 1999, 14:127-131.
90. Yakicier MC, Irmak MB, Romano A, et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999, 18:4879-4883.
91. Bae JJ, Rho JW, Lee TJ, et al. Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep 2007, 18:1007-1013.
92. Fujiwara Y, Hoon DS, Yamada T, et al. PTEN/MMACl mutation and frequent loss of heterozygosity identified in chromosome lOq in a subset of hepatocellular carcinomas. Jpn J Cancer Res 2000, 91:287-292.
93. Kawamura N, Nagai H, Bando K, et al. PTEN/MMACl mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 1999, 90:413-418.
94. Yao YJ, Ping XL, Zhang H, et al. PTEN/MMACl mutations in hepatocellular carcinomas. Oncogene 1999, 18:3181-3185.
95. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995, 11:447-449.
96. Oka Y, Waterland RA, Killian JK, et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002, 35:1153-1163.
97. Yamada T, De Souza AT, Finkelstein S, et al. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Nati Acad Sei USA 1997, 94:10351-10355.
98. Kim CJ, Cho YG, Park JY, et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer 2004, 40:136-141.
99. Jeannot E, Poussin K, Chiche L, et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1 alpha-mutated hepatocellular adenoma. Cancer Res 2007, 67:2611-2616.
100. Jeannot E, Wendum D, Paye F, et al. Hepatocellular adenoma displaying a HNF1 alpha inactivation in a patient with familial adenomatous polyposis coli. J Hepatol 2006, 45:883-886.
101. Pelletier L, Rebouissou S, Paris A, et al. Loss of hepatocyte nuclear factor 1 alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 2010, 51:557-566.
102. Rebouissou S, Imbeaud S, Balabaud C, et al. HNFlalpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem 2007, 282:14437-14446.
103. Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab 2004, 89:1476-1480.
104. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohis-tochemistry. Hepatology 2007, 46:740-748.